Dean Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Dean Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4M	Sell	21,156 -2	-0%	-$350	1.66%	6
2025 Q4	$3.6M	Buy	21,158 +654	+3%	+$100K	1.53%	9
2025 Q3	$2.7M	Hold	20,504	–	–	1.05%	23
2025 Q2	$2.18M	Buy	20,504 +4,012	+24%	+$436K	0.89%	38
2025 Q1	$2.05M	Buy	16,492 +366	+2%	+$47.7K	0.89%	34
2024 Q4	$1.99M	Buy	16,126 +2,108	+15%	+$248K	0.85%	39
2024 Q3	$1.56M	Buy	+14,018	New	+$1.54M	0.66%	85
2024 Q2	–	Sell	-11,889	Closed	-$1.43M	–	114
2024 Q1	$1.43M	Hold	11,889	–	–	0.83%	62
2023 Q4	$1.46M	Buy	11,889 +1,928	+19%	+$241K	0.9%	50
2023 Q3	$1.29M	Buy	+9,961	New	+$1.33M	0.97%	35

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Dean Capital Management's JAZZ Position: Q1 2026 in Review

Dean Capital Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 0.01% in Q1 2026, selling an estimated $350 and leaving 21,156 shares worth $4M. The position accounts for 1.66% of the portfolio, ranked #6.

Dean Capital Management first reported a position in JAZZ in Q3 2023 and has held it in 10 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Dean Capital Management held 21,156 shares of Jazz Pharmaceuticals worth $4M as of Q1 2026.
Dean Capital Management sold 2 Jazz Pharmaceuticals shares in Q1 2026, an estimated $350.
Jazz Pharmaceuticals made up 1.66% of Dean Capital Management's portfolio in Q1 2026, its #6 holding.
Dean Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Dean Capital Management's 13F filing for Q1 2026, filed 15 May 2026.